Patents Assigned to Bristol-Myers
  • Tricyclic compounds as anticancer agents
    Patent number: 9751879
    Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: September 5, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, George V. Delucca, Ashvinikumar V. Gavai, Claude A. Quesnelle, Patrice Gill, Daniel O'Malley, Wayne Vaccaro, Francis Y. Lee, Mikkel V. DeBenedetto, Andrew P. Degnan, Haiquan Fang, Matthew D. Hill, Hong Huang, William D. Schmitz, John E. Starrett, Jr., Wen-Ching Han, John S. Tokarski, Sunil Kumar Mandal
  • LXR modulators
    Patent number: 9751869
    Abstract: The present invention provides compounds of Formula I and Formula II: or pharmaceutically acceptable salts or solvates thereof, as modulators of liver X receptors (LXRs), and compositions comprising any of such novel compounds and methods of use thereof. These compounds are useful as medicaments for treatment and/or prophylaxis for diseases or conditions related to activity of LXRs.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 5, 2017
    Assignees: Bristol-Myers Squibb Company, Exelixis Patent Company LLC
    Inventors: Ellen K. Kick, Mandar Bodas, Raju Mohan, Brett B. Busch, Claudia Averbuj, Meriah Valente, Nicholas Wurtz, Prasanna Savanor Maddu Rao, Jeevanprakash Shetty, Alla Venu
  • THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20170247343
    Abstract: The present invention provides compounds of Formula (I): wherein A, X and Y are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 31, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Andrew Quoc Viet, Nicholas R. Wurtz
  • FUROPYRIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170247385
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 31, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Kyle J. Eastman, Zhongxing Zhang, Kyle E. Parcella, John F. Kadow
  • Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
    Patent number: 9745379
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 29, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
  • Macrocycles as factor XIa inhibitors
    Patent number: 9745313
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: August 29, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mimi L. Quan, Carl P. Decicco, James R. Corte, Cailan Wang
  • Compounds for the treatment of hepatitis C
    Patent number: 9745322
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: August 29, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhiwei Yin, Paul Michael Scola
  • Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
    Patent number: 9738655
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Charles G. Clarke, Leon M. Smith, II, Michael J. Orwat, Yoon Jeon, James R. Corte
  • Pyrrolotriazine kinase inhibitors
    Patent number: 9737542
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carolyn Diane Dzierba, Bireshwar Dasgupta, John E. Macor, Joanne J. Bronson, Ramkumar Rajamani, George N. Karageorge
  • Fused furans for the treatment of hepatitis C
    Patent number: 9738653
    Abstract: The disclosure provides compounds of formula I or II, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Kyle J. Eastman, Kyle E. Parcella
  • Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders
    Patent number: 9738642
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lawrence R. Marcin, Mendi A. Higgins, Joanne J. Bronson, F. Christopher Zusi, John E. Macor, Min Ding
  • Inhibitors of lysine methyl transferase
    Patent number: 9738630
    Abstract: There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases, utilizing the compounds of the invention.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 22, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kyoung S. Kim, Liping Zhang, Ashok Vinayak Purandare, Steven P. Seitz
  • Immunomodulators
    Patent number: 9732119
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 15, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • TIED-BACK BENZAMIDE DERIVATIVES AS POTENT ROCK INHIBITORS
    Publication number: 20170226105
    Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: August 20, 2015
    Publication date: August 10, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Zilun Hu, Doree F. Sitkoff, Mimi L. Quan
  • ROR? modulators
    Patent number: 9725443
    Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: August 8, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: T. G. Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
  • Substituted 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as factor XIa inhibitors
    Patent number: 9725435
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: August 8, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael J. Orwat, Donald J. P. Pinto, Leon M. Smith, II, James R. Corte, Shefali Srivastava
  • Tricyclic compounds as anticancer agents
    Patent number: 9725449
    Abstract: The present invention is directed to tricyclic compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 8, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Derek J. Norris, Wayne Vaccaro, Mikkel V. DeBenedetto, Andrew P. Degnan, George V. Delucca, Jeffrey A. Deskus, Wen-Ching Han, Godwin Kwame Kumi, William D. Schmitz, John E. Starrett, Jr., Matthew D. Hill, Hong Huang
  • Process for the preparation of cycloheptapyridine CGRP receptor antagonists
    Patent number: 9718845
    Abstract: The disclosure generally relates to a process for the preparation of compounds of formula I, including synthetic intermediates which are useful in the process.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: August 1, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: David K. Leahy, Yu Fan, Collin Chan, Lopa V. Desai, Sunil S. Patel, Masano Sugiyama
  • GSK-3 inhibitors
    Patent number: 9718804
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: August 1, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Vivekananda M. Vrudhula, Senliang Pan, Prasanna Sivaprakasam, John E. Macor
  • Flange extender
    Patent number: D793552
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 1, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Eric Schiller, Christina Joy Laskar, Mitali Aon, Richard Caizza, Jon Bell